The CME process has seen unprecedented improvements over the past 2 years, but old perceptions of "scratching the sponsor’s back"—which admittedly occurred in the past—persist. Thus, practitioners must actively participate in providing feedback about CME offerings regarding the extremes: blatant bias or exemplary, evidenced-based neutrality.
Finally, although psychopharmacologic advances represent a large proportion of the new knowledge in psychiatry, it is my hope that pharmaceutical companies would support CME programs that update practitioners about progress in psychosocial interventions as well.
Henry A. Nasrallah, MD
Editor-in-Chief